11 Questions
What is the main difference in T cell activation between CD28 and 4-1BB in CD19 CAR T cells?
CD28 induces rapid T cell activation, whereas 4-1BB induces slower T cell activation.
How do the metabolic pathways differ between CD28 and 4-1BB CAR T cells?
CD28 CAR T cells undergo aerobic glycolysis, whereas 4-1BB CAR T cells undergo oxidative metabolism.
What is the duration of persistence for 4-1BB CAR T cells compared to CD28 CAR T cells?
4-1BB CAR T cells persist for up to 5 years, whereas CD28 CAR T cells persist for approximately 3 months.
What is the function of the extracellular binding domain in a CAR?
The extracellular binding domain recognizes and binds to a specific target antigen on tumor cells.
What is the purpose of the hinge domain in a CAR?
The hinge domain provides flexibility and spacer function between the extracellular binding domain and the transmembrane domain.
What are the advantages of using CD19 as a target antigen in CAR T cell therapy?
CD19 is a specific antigen expressed on B cells, allowing for targeted therapy with minimal off-tumor effects.
What is the role of the intracellular domain in a CAR?
The intracellular domain transduces signals to activate T cells and induce effector functions.
What are the advantages of using 4-1BB as a co-stimulatory molecule in CAR T cells?
4-1BB promotes slower T cell activation, leading to prolonged persistence and reduced toxicity.
How does the structure of a CAR impact its function?
The structure of a CAR, including the extracellular binding domain, hinge domain, transmembrane domain, and intracellular domain, determines its ability to target and activate T cells.
What are the implications of using different target antigens in CAR T cell therapy?
Different target antigens can impact the specificity and efficacy of CAR T cell therapy, as well as the risk of off-tumor effects.
What are the advantages of using CAR T cells compared to TILs and TCR-based strategies?
CAR T cells can be rapidly expanded and modified, and can target specific tumor antigens, allowing for more targeted therapy.
This quiz covers the toxicities related to CAR T-cell therapy, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and on-target off-tumor toxicity. It also explores strategies to reduce side effects and antigen-escape after CAR T-cell therapy.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
